The long-duration response to l-dopa in the treatment of early PD

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Neurology

• Publication date

  2000-05-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.54.10.1910PMID 10822428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of long-duration response to levodopa over time in PD

  1999cited by this paper
• Pharmacodynamics of the long-duration response to levodopa in PD

  1999cited by this paper
• An algorithm (decision tree) for the management of Parkinson's disease

  1998cited by this paper
• An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. American Academy of Neurology.

  1998cited by this paper
• Long‐duration response to levodopa influences the pharmacodynamics of short‐duration response in Parkinson's disease

  1997cited by this paper
• Short‐term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease

  1997cited by this paper
• The response to levodopa in parkinson's disease: Imposing pharmacological law and order

  1996cited by this paper
• The subacute levodopa test for evaluating long‐duration response in parkinson's disease

  1995cited by this paper
• Usefulness of movement time in the assessment of Parkinson's disease

  1994cited by this paper
• Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon.

  1992cited by this paper
• The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.

  1988cited by this paper
• Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale

  1987cited by this paper
• Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients

  1986cited by this paper
• L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.

  1971cited by this paper

• Characteristics of responders to interventions for Parkinson disease: a scoping systematic review

  2025influential citation
• Parkinson's disease progression is multifaceted: Evidence for the underlying benchmarks.

  2024cites this paper
• Neurohormetic phytochemicals in the pathogenesis of neurodegenerative diseases

  2022cites this paper
• Medical treatment of the motor features of Parkinson disease

  2021cites this paper
• Structural MRI substrate of long-duration response to levodopa in Parkinson’s disease: an exploratory study

  2021cites this paper
• Hormesis: A potential strategic approach to the treatment of neurodegenerative disease.

  2020cites this paper
• Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis

  2018cites this paper
• Hormetic approaches to the treatment of Parkinson's disease: Perspectives and possibilities

  2018cites this paper
• The missing, the short, and the long: Levodopa responses and dopamine actions

  2017influential citation
• Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease

  2016cites this paper
• Long Duration Response to Levodopa in Advanced Parkinson' s Disease Patients Treated With Subthalamic Deep Brain Stimulation

  2014cites this paper
• Pharmacological Properties of Levodopa

  2014cites this paper
• The role of neuroplasticity in dopaminergic therapy for Parkinson disease

  2013cites this paper
• Longitudinal study of levodopa in Parkinson's disease: Effects of the advanced disease phase

  2013cites this paper
• Preservation of function in Parkinson's disease: what's learning got to do with it?

  2011cites this paper
• The role of the long-duration response to levodopa in Parkinson’s disease

  2010cites this paper
• A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease.

  2010cites this paper
• Levodopa therapeutics for Parkinson's disease: new developments.

  2009cites this paper
• Levodopa in the treatment of Parkinson’s disease

  2009cites this paper
• [Reconsiderations in the treatment of Parkinson's disease with levodopa: some pharmacodynamic evidence].

  2009cites this paper
• Reconsideraciones en el tratamiento de la enfermedad de Parkinson con levodopa: evidencias farmacodinámicas

  2009influential citation
• The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.

  2009cites this paper
• COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinson’s disease (PD): relevance for motor and non-motor features

  2008influential citation
• Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?

  2008cites this paper
• Reply: Continuous stimulation: Is it the answer to the motor complications of levodopa

  2008cites this paper
• Continuous dopaminergic stimulation: Is it the answer to the motor complications of levodopa?

  2008cites this paper
• Chapter 6 – Medical treatment of Parkinson disease

  2007cites this paper
• Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease

  2007cites this paper
• Long-duration response to levodopa in patients with advanced Parkinson disease treated with subthalamic deep brain stimulation.

  2006cites this paper
• Orally disintegrating carbidopa/levodopa

  2006cites this paper
• Longitudinal study of the motor response to levodopa in Parkinson's disease

  2006cites this paper
• Levodopa in the treatment of Parkinson's disease.

  2006cites this paper
• Movement time and aging: a normative study in healthy subjects with the “Movement Time Analyzer®”

  2005cites this paper
• The Evolution and Potential of the National Parkinson Organizations: A Brief Overview

  2004cites this paper
• Normal striatal D2 receptor binding in idiopathic restless legs syndrome with periodic leg movements in sleep

  2004cites this paper
• Levodopa strengths and weaknesses

  2002cites this paper
• Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease

  2002cites this paper
• Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease

  2002cites this paper
• The Long and the Short of It

  2001cites this paper
• Complications and limitations of drug therapy for Parkinson's disease.

  2000cites this paper